These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 21083323)

  • 1. Application of the Gyrolab™ platform to ligand-binding assays: a user's perspective.
    Mora JR; Obenauer-Kutner L; Vimal Patel V
    Bioanalysis; 2010 Oct; 2(10):1711-5. PubMed ID: 21083323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accelerating Regulated Bioanalysis for Biotherapeutics: Case Examples Using a Microfluidic Ligand Binding Assay Platform.
    Liu R; Hoffpauir B; Chilewski SD; Gamberdella J; Kavita U; Duo J; Gleason C; Zhang Y; Pillutla R; DeSilva B; Hamuro L
    AAPS J; 2017 Jan; 19(1):82-91. PubMed ID: 27796911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation into the applicability of the centrifugal microfluidics platform for the development of protein-ligand binding assays incorporating enhanced green fluorescent protein as a fluorescent reporter.
    Puckett LG; Dikici E; Lai S; Madou M; Bachas LG; Daunert S
    Anal Chem; 2004 Dec; 76(24):7263-8. PubMed ID: 15595868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An integrated bioanalytical platform for supporting high-throughput serum protein binding screening.
    Zhang J; Shou WZ; Vath M; Kieltyka K; Maloney J; Elvebak L; Stewart J; Herbst J; Weller HN
    Rapid Commun Mass Spectrom; 2010 Dec; 24(24):3593-601. PubMed ID: 21080511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microfluidic devices for bioapplications.
    Yeo LY; Chang HC; Chan PP; Friend JR
    Small; 2011 Jan; 7(1):12-48. PubMed ID: 21072867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in microfluidics for drug discovery.
    Lombardi D; Dittrich PS
    Expert Opin Drug Discov; 2010 Nov; 5(11):1081-94. PubMed ID: 22827746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A microfluidic platform for sequential ligand labeling and cell binding analysis.
    Sui G; Lee CC; Kamei K; Li HJ; Wang JY; Wang J; Herschman HR; Tseng HR
    Biomed Microdevices; 2007 Jun; 9(3):301-5. PubMed ID: 17195108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microfluidic platforms for lab-on-a-chip applications.
    Haeberle S; Zengerle R
    Lab Chip; 2007 Sep; 7(9):1094-110. PubMed ID: 17713606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid development of multiple 'fit-for-purpose' assays on an automatic microfluidic system using a streamlined process in support of early biotherapeutics discovery programs.
    Liu R; Pillutla R; DeSilva B; Zhang YJ
    Bioanalysis; 2013 Jul; 5(14):1751-63. PubMed ID: 23862707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ligand-binding assays: risk of using a platform supported by a single vendor.
    Yohrling J
    Bioanalysis; 2009 Jun; 1(3):629-36. PubMed ID: 21083158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-cell-reporter-gene-based biosensing systems on a compact disk microfluidics platform.
    Rothert A; Deo SK; Millner L; Puckett LG; Madou MJ; Daunert S
    Anal Biochem; 2005 Jul; 342(1):11-9. PubMed ID: 15958175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of a Gyrolab™ assay for quantification of rituximab in human serum.
    Liu XF; Wang X; Weaver RJ; Calliste L; Xia C; He YJ; Chen L
    J Pharmacol Toxicol Methods; 2012; 65(3):107-14. PubMed ID: 22406436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platform switching from ELISA to Gyrolab™: a novel generic reagent omits the need to change critical reagents.
    Jordan G; Moheysen-Zadeh M; Heinrich J; Staack RF
    Bioanalysis; 2016 Apr; 8(8):807-14. PubMed ID: 26975340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiplexed analysis of protein-ligand interactions by fluorescence anisotropy in a microfluidic platform.
    Cheow LF; Viswanathan R; Chin CS; Jennifer N; Jones RC; Guccione E; Quake SR; Burkholder WF
    Anal Chem; 2014 Oct; 86(19):9901-8. PubMed ID: 25207435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Droplet-based microfluidics: enabling impact on drug discovery.
    Dressler OJ; Maceiczyk RM; Chang SI; deMello AJ
    J Biomol Screen; 2014 Apr; 19(4):483-96. PubMed ID: 24241711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microfluidic serial dilution cell-based assay for analyzing drug dose response over a wide concentration range.
    Sugiura S; Hattori K; Kanamori T
    Anal Chem; 2010 Oct; 82(19):8278-82. PubMed ID: 20822164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stem cells in microfluidics.
    van Noort D; Ong SM; Zhang C; Zhang S; Arooz T; Yu H
    Biotechnol Prog; 2009; 25(1):52-60. PubMed ID: 19205022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Droplet-based microfluidic platform for heterogeneous enzymatic assays.
    Chang C; Sustarich J; Bharadwaj R; Chandrasekaran A; Adams PD; Singh AK
    Lab Chip; 2013 May; 13(9):1817-22. PubMed ID: 23507976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing a novel fiber optic fluorescence device for multiplexed high-throughput cytotoxic screening.
    Lee D; Barnes S
    J Exp Ther Oncol; 2010; 8(3):235-45. PubMed ID: 20734922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ligand-receptor interaction platforms and their applications for drug discovery.
    Fang Y
    Expert Opin Drug Discov; 2012 Oct; 7(10):969-88. PubMed ID: 22860803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.